旅行疫苗市场:现状分析与预测(2024年～2032年)

旅行疫苗市场预计将呈现约9.5%的成长率。这主要是由于外科手术尤其是骨科手术的增加，增加了对DVT预防和治疗的需求。疫苗开发和输送系统的创新也提高了旅游疫苗的有效性和可近性。预计这将进一步推动市场成长。例如，2021 年12 月，Emergent BioSolutions Inc. 宣布其第一阶段试验EBS-UFV-001 的第一项参与者研究已宣布，该研究旨在研究其在研通用流感疫苗候选药物的安全性、耐受性和免疫原性。这最新版本的候选流感疫苗含有多种成分，旨在诱导针对甲型流感病毒的广泛的、跨季节的免疫力。

市场依疾病类型分为肝炎、伤寒、流感、百白破、黄热病等。由于甲型肝炎和乙型肝炎的风险不断增加，尤其是在新兴市场，肝炎类别预计将占据旅行疫苗市场的最大市场占有率。旅客寻求这些疫苗是因为这些卫生当局和国家的建议，以及在某些情况下的要求。这些宣传活动、公司旅行政策以及国际旅行的出现也促进了这一增长。此外，肝炎疫苗的可用性、安全性和有效性也刺激了旅客对肝炎疫苗的高需求。另一方面，疫苗是旅行卫生的重要组成部分，因为参与政府旅行卫生评估有助于制定旅行卫生措施。

依旅行者类型，市场分为国内和国际。其中，国内类别预计将占据旅行疫苗市场的最大市场占有率，因为人们越来越多地前往本国不同地区，从而带来不同的感染疾病风险。国内旅客从一个地区到另一个地区，或从城市到农村地区，或到疾病流行地区，因此可能会在所到地区接触蜱传脑炎或伤寒等疾病的疫苗接种。由于大流行后健康问题加剧，以及政府鼓励当地旅游业的活动，人们可能会在自己的国家/地区进行国内旅行并接种疫苗以确保安全旅行。这一趋势对旅行疫苗的整体需求产生了积极影响，并正在推动全球市场的成长。

依年龄组，市场分为儿科、成人和老年。其中，成人品类细分市场也显着提振了旅游疫苗市场。成年人，尤其是 18 岁至 60 岁之间的成年人，占休閒和商务旅行人口的大多数。该群体更有可能出国旅行，包括前往需要接种黄热病、甲型肝炎、乙型肝炎和伤寒疫苗的高风险地区。成年人也更有可能遵循疫苗接种建议，因为他们通常对自己的健康决定负责。成人独自旅行和探险旅行的趋势进一步强化了全面疫苗接种的需求并推动市场成长。

为了更了解旅行疫苗的市场介绍，市场包括北美（美国、加拿大、欧洲其他地区）、欧洲（德国、英国、法国、西班牙、义大利、欧洲其他地区）、亚太地区（中国、根据世界其他地区（日本、印度、亚太其他地区）和世界其他地区的全球影响力进行分析。由于国际旅行频繁、卫生法规严格以及人们对旅行相关健康风险的认识不断增强，北美旅行疫苗市场的特点是需求强劲。该地区的市场得到了完善的医疗基础设施、广泛的疫苗覆盖率以及疾病预防控制中心等卫生当局建议的积极疫苗接种政策的支持。这家北美公司提供全面的疫苗组合，利用先进的医疗技术进行分发，并专注于旅行者教育以确保广泛接种疫苗。出境旅游和商务旅行的增加进一步推动了该市场的成长，凸显了该地区在全球旅行卫生措施中的关键作用。

市场上的主要公司包括默克（Merck & Co., Inc.）、辉瑞公司（Pfizer Inc.）、雅培製药有限公司（Serum Institute of India Pvt. Ltd.）、阿斯特捷利康製药公司（AstraZeneca） 。

目录

第1章 市场简介

• 市场定义
• 主要目的
• 相关利益者
• 限制事项

第2章 调查手法或前提条件

• 调查流程
• 调查手法
• 受访者简介

第3章 摘要整理

• 产业摘要
• 各市场区隔预测
  • 市场成长的强度
• 地区展望

第4章 市场动态

• 促进因素
• 机会
• 阻碍因素
• 趋势
• PESTEL分析
• 需求面分析
• 供给面分析
  • 合併和收购
  • 投资情势
  • 产业洞察：主要新创公司及其独特策略

第5章 价格分析

• 各地区价格分析
• 价格的影响因素

第6章 全球旅行疫苗市场收益，2022-2032年

第7章 各疾病类型的市场分析

• 肝炎
• 伤寒症
• 流感
• DPT
• 黄热病
• 其他

第8章 各旅客类型的市场分析

• 国内
• 国际

第9章 各年龄层的市场分析

• 儿童
• 成人
• 老年人

第10章 各地区的市场分析

• 北美
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 全球其他地区

第11章 价值链分析

• 限制分析
• 市场参与企业一览

第12章 竞争情形

• 竞争仪表板
• 竞争市场定位分析
• 波特的五力分析

第13章 企业简介

• Merck & Co., Inc.
• Sanofi
• Novartis AG
• Pfizer Inc.
• EMERGENT
• Abbott
• Serum Institute of India Pvt. Ltd.
• Takeda Pharmaceutical Company Limited
• AstraZeneca
• GSK plc.

第14章 缩写与前提条件

第15章 附录

The global travel vaccine ongoing and forthcoming encompasses vaccines manufactured for protecting travelers against diseases that are usually identifiable in diverse countries and are thus likely to affect travelers, these vaccines include Hepatitis A and B, typhoid, yellow fever, and rabies. Some of the forces that are currently fueling this market are the global traffic upsurge, improved consciousness of health risks associated with traveling, and official health guidelines and requirements from various governments and health institutions. Also, new technologies, new disease threats, and developments in travel-related infrastructures added to the market growth, so, traveling vaccinations are a key part of travel requirements.

The market for travel vaccine market is set to exhibit a growth rate of about 9.5%. This is mainly due to the rise in surgical procedures, especially orthopedic surgeries, which increases the need for DVT prophylaxis and treatment. Also, innovations in vaccine development and delivery systems enhance the efficacy and accessibility of travel vaccines. This will further boost market growth. For instance, In December 2021, Emergent BioSolutions Inc. declared the first participant dosed in its phase 1 study, EBS-UFV-001, studying the safety, tolerability, and immunogenicity of its investigational universal influenza vaccine candidate. The current and updated version of this influenza vaccine candidate includes multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses.

Based on the disease type, the market is segmented into hepatitis, typhoid, influenza, DPT, yellow fever, and others. The hepatitis category is expected to have the largest market share of the travel vaccine market due to the increased risks of Hepatitis A and B in most tourism; especially those in the developing world. The traveling public seeks these vaccines because of the recommendations and in some cases, requirements of such health organizations and countries. These are awareness campaigns, corporate travel policies, and the emergence of international travel also catalyzed this growth. Further, accessibility of Hepatitis vaccines, safety, and efficacy also add to the high demand for Hepatitis vaccines midst travelers while government participation in touting travel health assessments contributes towards the formulation of travel health measures hence the vaccines in question form a significant cog in travel health.

Based on the tourist type, the market is segmented into domestic and international. Among these, the domestic category is expected to have the largest market share of the travel vaccine market due to the rising number of times that people visit different areas in their own countries, which puts them at different risks of getting diseases. Domestic tourists move from one region to another or from urban areas to rural areas or areas where the diseases are endemic and therefore, they require vaccinations of the diseases that are prevalent in the region they are visiting such as tick-borne encephalitis or typhoid fever. Due to government campaigns espousing local tourism as well as the post-pandemic increased concerns for health, people travel domestically within their countries and are likely to get vaccinated to ensure safe travels. This trend has a positive impact on the overall demand for travel vaccines and thus fuels the growth of the global market.

Based on the age group, the market is segmented into pediatrics, adults, and geriatrics. Among these, the adult category segment also significantly boosts the travel vaccine market. Adults, especially those between 18 and 60, constitute a major portion of the traveling population for both leisure and business purposes. This demographic is more likely to travel to international destinations, including regions with higher health risks, necessitating vaccinations for diseases like yellow fever, Hepatitis A and B, and typhoid. Additionally, as adults are typically responsible for their health decisions, they are more likely to adhere to vaccination recommendations. The increasing trend of solo travel and adventure tourism among adults further elevates the need for comprehensive vaccination, driving market growth.

For a better understanding of the market adoption of travel vaccines, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North American travel vaccine market is characterized by robust demand driven by a high volume of international travel, stringent health regulations, and increasing awareness of travel-related health risks. The region's market is bolstered by established healthcare infrastructure, widespread availability of vaccines, and proactive vaccination policies recommended by health authorities such as the CDC. Companies in North America focus on offering comprehensive vaccine portfolios, leveraging advanced healthcare technologies for distribution, and emphasizing traveler education to ensure widespread adoption of vaccinations. The market's growth is further propelled by rising outbound tourism and business travel, highlighting the region's pivotal role in global travel health initiatives.

Some of the major players operating in the market include Merck & Co., Inc.; Sanofi; Novartis AG; Pfizer Inc.; EMERGENT; Abbott; Serum Institute of India Pvt. Ltd.; Takeda Pharmaceutical Company Limited; AstraZeneca; and GSK plc.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Global Travel Vaccine Market
• 2.2. Research Methodology of the Global Travel Vaccine Market
• 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

• 3.1. Industry Synopsis
• 3.2. Segmental Outlook
  • 3.2.1. Market Growth Intensity
• 3.3. Regional Outlook

4.MARKET DYNAMICS

• 4.1. Drivers
• 4.2. Opportunity
• 4.3. Restraints
• 4.4. Trends
• 4.5. PESTEL Analysis
• 4.6. Demand Side Analysis
• 4.7. Supply Side Analysis
  • 4.7.1. Merger & Acquisition
  • 4.7.2. Investment Scenario
  • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

• 5.1. Regional Pricing Analysis
• 5.2. Price Influencing Factors

6.GLOBAL TRAVEL VACCINE MARKET REVENUE (USD BN), 2022-2032F

7.MARKET INSIGHTS BY DISEASE TYPE

• 7.1. Hepatitis
• 7.2. Typhoid
• 7.3. Influenza
• 7.4. DPT
• 7.5. Yellow Fever
• 7.6. Others

8.MARKET INSIGHTS BY TOURIST TYPE

• 8.1. Domestic
• 8.2. International

9.MARKET INSIGHTS BY AGE GROUP

• 9.1. Pediatrics
• 9.2. Adults
• 9.3. Geriatrics

10.MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11.VALUE CHAIN ANALYSIS

• 11.1. Marginal Analysis
• 11.2. List of Market Participants

12.COMPETITIVE LANDSCAPE

• 12.1. Competition Dashboard
• 12.2. Competitor Market Positioning Analysis
• 12.3. Porter Five Forces Analysis

13.COMPANY PROFILED

• 13.1. Merck & Co., Inc.
  • 13.1.1. Company Overview
  • 13.1.2. Key Financials
  • 13.1.3. SWOT Analysis
  • 13.1.4. Product Portfolio
  • 13.1.5. Recent Developments
• 13.2. Sanofi
• 13.3. Novartis AG
• 13.4. Pfizer Inc.
• 13.5. EMERGENT
• 13.6. Abbott
• 13.7. Serum Institute of India Pvt. Ltd.
• 13.8. Takeda Pharmaceutical Company Limited
• 13.9. AstraZeneca
• 13.10. GSK plc.

14.ACRONYMS & ASSUMPTION

15.ANNEXURE